Anatomical Therapeutic Chemical • L04AA21 • efalizumab

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AA01 cyclosporine Indicated for: immunosuppression

L04AA03 anti-lymphocyte immunoglobulin (horse) Indicated for: immunosuppression

L04AA03 human anti-lymphocyte immunoglobulin Indicated for: immunosuppression

L04AA04 anti-lymphocyte immunoglobulin Indicated for: immunosuppression

L04AA04 anti-lymphocyte immunoglobulin (rabbit) Indicated for: immunosuppression

L04AA04 rabbit anti-human lymphocyte immunoglobulin Indicated for: prevention and treatment of transplant rejection

L04AA06 mycophenolate Indicated for: prevention of transplant rejection

L04AA06 mycophenolate mofetil Indicated for: prevention of transplant rejection

L04AA08 daclizumab Indicated for: multiple sclerosis

L04AA10 sirolimus Indicated for: prevention of transplant rejection

L04AA13 leflunomide Indicated for: rheumatoid arthritis

L04AA17 adalimumab Indicated for: inflammatory bowel disease

L04AA21 efalizumab Indicated for: psoriasis

L04AA23 natalizumab Indicated for: multiple sclerosis; Crohn's disease

L04AA24 abatacept Indicated for: rheumatoid arthritis

L04AA26 belimumab Indicated for: systemic lupus erythematosus

L04AA28 belatacept Indicated for: prevention of transplant rejection

L04AA31 teriflunomide Indicated for: multiple sclerosis

L04AA32 apremilast Indicated for: psoriasis; psoriatic arthritis

L04AA33 vedolizumab Indicated for: inflammatory bowel disease

L04AA34 alemtuzumab Indicated for: multiple sclerosis; chronic lymphocytic leukemia

L04AA40 cladribine Indicated for: multiple sclerosis; chronic lymphocytic leukemia

L04AA43 ravulizumab Indicated for: complement-mediated disorders

L04AA50 ponesimod Indicated for: multiple sclerosis

L04AA58 efgartigimod alfa Indicated for: myasthenia gravis

L04AA60 remibrutinib Indicated for: chronic spontaneous urticaria

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AF Janus-associated kinase (JAK) inhibitors

L04AG Monoclonal antibodies

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AL Neonatal fragment crystallizable receptor (fcrn) inhibitors

L04AX Other immunosuppressants

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various